![](https://investorshub.advfn.com/uicon/69437.png?cb=1592321837)
Monday, June 15, 2020 2:32:06 PM
@humanigen Lenzilumab in high-risk #COVID19 patients came back with promising results! This treatment showed a rapid recovery in patients and lead to their discharge after a median of 5 days.
CTI Clinical Trials
@CTIClinical
The data from the first clinical trial using @humanigen Lenzilumab in high-risk #COVID19 patients came back with promising results! This treatment showed a rapid recovery in patients and lead to their discharge after a median of 5 days.https://t.co/WqFipNoxpx
— CTI Clinical Trials (@CTIClinical) June 15, 2020
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM